Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00474240 · ClinicalTrials.gov registry record · Phase 2
AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate Hypercholesterolemia
A Phase 2 study, sponsored by Aegerion Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 157
- Enrollment target
NCT00474240 is a Phase 2 study that has completed, run by Aegerion Pharmaceuticals. The registered enrollment target is 157 participants.
The verdict
NCT00474240, a Phase 2 study, has completed, sponsored by Aegerion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 157 participants
- Enrollment target
Study Summary
The purpose of this study is to test the effectiveness of the study drug, AEGR-733 alone and in combination with the medication, atorvastatin (Lipitor), on cholesterol in volunteers with moderately high cholesterol.
Interventions
- DRUG Placebo
- DRUG Atorvastatin 20 mg
- DRUG AEGR-733 5 mg
- DRUG AEGR-733 10 mg
- DRUG AEGR-733 5 mg + atorvastatin 20 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 157 participants |
| Start Date | 2007-04 |
| Est. Completion | 2008-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00474240
The ClinicalTrials.gov registry entry for NCT00474240 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 157 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aegerion Pharmaceuticals, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT00474240 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00474240 about?
NCT00474240 is a clinical study titled "AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate Hypercholesterolemia". The purpose of this study is to test the effectiveness of the study drug, AEGR-733 alone and in combination with the medication, atorvastatin (Lipitor), on cholesterol in volunteers with moderately high cholesterol.
What is the current status of trial NCT00474240?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 157 participants. The study started on 2007-04. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00474240?
The interventions under investigation include: Placebo (DRUG), Atorvastatin 20 mg (DRUG), AEGR-733 5 mg (DRUG), AEGR-733 10 mg (DRUG), AEGR-733 5 mg + atorvastatin 20 mg (DRUG).
Who is sponsoring clinical trial NCT00474240?
This trial is sponsored by Aegerion Pharmaceuticals, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.